^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CTX110

    i
    Other names: CTX110, CTX-110, CTX 110, CTX 101, anti-CD19+ CAR-T cells
    Company:
    CRISPR Therap
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    8ms
    A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) (clinicaltrials.gov)
    P1/2, N=227, Active, not recruiting, CRISPR Therapeutics AG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CTX110
    over1year
    A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) (clinicaltrials.gov)
    P1/2, N=227, Recruiting, CRISPR Therapeutics AG | Phase classification: P1 --> P1/2 | N=143 --> 227
    Phase classification • Enrollment change
    |
    CTX110
    almost2years
    CTX110 ALLOGENEIC CRISPR-CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: RESULTS FROM THE PHASE 1 DOSE ESCALATION CARBON STUDY (EBMT 2023)
    Pts received standard lymphodepleting chemotherapy (LDC) with fludarabine 30mg/m2 and cyclophosphamide 500mg/m2 for 3 days, followed by CTX110. CTX110 at DL≥3 or higher resulted in clinically meaningful ORR, CR rates, and durable remissions, accompanied by a favorable safety profile in pts with R/R LBCL. Nearly half of all patients who achieved a CR maintained it out to at least 6 months. CTX110 offers a potential novel off-the-shelf treatment option with a median time from enrollment to LDC of 2 days.
    Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • B2M (Beta-2-microglobulin)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • fludarabine IV • CTX110
    2years
    CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study (ASH 2022)
    Pts received standard lymphodepleting chemotherapy (LDC) with fludarabine 30mg/m2 and cyclophosphamide 500mg/m2 for 3 days, followed by CTX110. In a heavily pre-treated patient population with R/R LBCL (46.9% with 3 or more prior lines of therapy), CTX110 at DL≥3 or higher resulted in clinically meaningful ORR, CR rates, and durable remissions, accompanied by a favorable safety profile during dose escalation. Nearly half of all patients who achieved a CR maintained it out to at least 6 months. CTX110 offers a potential off-the-shelf treatment option; only 2 enrolled pts were unable to receive CTX110 and the median time from enrollment to LDC was just 2 days, followed by infusion of CTX110 a median of 3 days afterwards.
    Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
    |
    CD19 (CD19 Molecule) • B2M (Beta-2-microglobulin)
    |
    cyclophosphamide • fludarabine IV • CTX110